Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.

doi:10.1016/j.xcrm.2021.100411

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.

Cell reports. Medicine - 19 Oct 2021

Liu Sixue, Knochelmann Hannah M, Lomeli Shirley H, Hong Aayoung, Richardson Mary, Yang Zhentao, Lim Raymond J, Wang Yan, Dumitras Camelia, Krysan Kostyantyn, Timmers Cynthia, Romeo Martin J, Krieg Carsten, O'Quinn Elizabeth C, Horton Joshua D, Dubinett Steve M, Paulos Chrystal M, Neskey David M, Lo Roger S

Abstract excerpt

Neoadjuvant PD-1 blockade may be efficacious in some individuals with high-risk, resectable oral cavity head and neck cancer. To explore correlates of response patterns to neoadjuvant nivolumab treatment and post-surgical recurrences, we analyzed longitudinal tumor and blood samples in a cohort of 12 individuals displaying 33% responsiveness. Pretreatment tumor-based detection of FLT4 mutations and PTEN signature...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Neoadjuvant Therapy

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to Th17 Cells

Share to Vascular Endothelial Growth Factor Receptor-3

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34755131
DOI: 10.1016/j.xcrm.2021.100411
PMCID: PMC8561238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.PMID 34755131Read ↗

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesSemantic proximity Read ↗

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersSemantic proximity Read ↗

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapySemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

Single-cell sequencing reveals tumor microenvironment features associated with the response to neoadjuvant immunochemotherapy in oral squamous cell carcinomaSemantic proximity Read ↗

Deciphering the Immune Landscape of Head and Neck Squamous Cell Carcinoma: A Single-Cell Transcriptomic Analysis of Regulatory T Cell Responses to PD-1 Blockade TherapySemantic proximity Read ↗

Alterations in Intratumoral Immune Response Before and Early-on-Treatment of Nivolumab in Unresectable Advanced or Recurrent Gastric CancerSemantic proximity Read ↗

Oligoclonal B cell Expansion and Passenger Fusion Genes Predict Response to Nivolumab in Recurrent Ovarian Cancer: Phase II Kyoto TrialSemantic proximity Read ↗

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for CancerSemantic proximity Read ↗

Connecting Baseline Immune Exhaustion in Hot Tumors to Oral Cancer Recurrence and Nodal MetastasisSemantic proximity Read ↗

Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.